GenetaStix Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

GenetaStix General Information

Description

Producer of antibody therapeutics. The company engages itself in the production of human monoclonal antibody therapeutics to fight cancer, infectious and autoimmune diseases and other life threatening and debilitating diseases.

Contact Information

Website
www.genetastix.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 780 Montague Expressway
  • Suite 303
  • San Jose, CA
  • United States
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Acquirer
Adimab
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 780 Montague Expressway
  • Suite 303
  • San Jose, CA
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GenetaStix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 26-Jul-2007 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Nov-2000 Completed Startup
To view GenetaStix’s complete valuation and funding history, request access »

GenetaStix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view GenetaStix’s complete cap table history, request access »

GenetaStix Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

GenetaStix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20030152913-A1 High throughput screening of antibody libraries against membrane proteins; chemokines; infection inhibition Active 08-Feb-2002
US-7138496-B2 Antibody that binds to loop 6 of human cxcr4, especially a single chain antibody Inactive 08-Feb-2002
US-7005503-B2 High throughput screening of antibody libraries against membrane proteins; chemokines; infection inhibition Inactive 08-Feb-2002
US-20030206909-A1 Antibody that binds to loop 6 of human cxcr4, especially a single chain antibody Active 08-Feb-2002
AU-2003209059-A8 Human monoclonal antibodies against membrane proteins Inactive 08-Feb-2002 C07K16/2866
To view GenetaStix’s complete patent history, request access »

GenetaStix Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fortune Venture Investment Group Venture Capital Minority
Kenson Ventures Venture Capital Minority
To view GenetaStix’s complete investors history, request access »

Ready to get started?

Request a free trial

GenetaStix FAQs

  • When was GenetaStix founded?

    GenetaStix was founded in 2000.

  • Where is GenetaStix headquartered?

    GenetaStix is headquartered in San Jose, CA.

  • What industry is GenetaStix in?

    GenetaStix’s primary industry is Biotechnology.

  • Is GenetaStix a private or public company?

    GenetaStix is a Private company.

  • What is GenetaStix’s current revenue?

    The current revenue for GenetaStix is .

  • How much funding has GenetaStix raised over time?

    GenetaStix has raised $3.5M.

  • Who are GenetaStix’s investors?

    Fortune Venture Investment Group and Kenson Ventures have invested in GenetaStix.

  • When was GenetaStix acquired?

    GenetaStix was acquired on 26-Jul-2007.

  • Who acquired GenetaStix?

    GenetaStix was acquired by Adimab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »